Xylem Inc.: A Deep Value Investment Study

Is This Business Simple, Transparent, and Worth Holding for the Long Term

I think it is relatively easy to understand, but not ultra-simple. What makes it easy: water is a necessity, and equipment and services are intuitive. What makes it complex: it spans projects, equipment, software, aftermarket, leasing, industrial processes, public spending, and international markets, and its financials also carry the integration effects following the Evoqua acquisition. So you need to read project cadence, orders, foreign exchange, working capital, and acquisition amortization to avoid misjudging it.

On revenue stability, this is not a business with "no quarterly fluctuation at all," but long-term demand is relatively solid. One very persuasive fact: under the 2020 pandemic shock, Xylem's revenue fell from $5.249 billion in 2019 to $4.876 billion, yet operating profit was still $367 million and operating cash flow still $824 million, showing considerable resilience in a headwind environment.

On cost structure, in 2025 the company had revenue of $9.035 billion, cost of $5.560 billion, gross profit of $3.475 billion, and a gross margin of about 38.5%; SG&A was $1.923 billion, R&D $226 million, and operating profit $1.192 billion. Capital-expenditure intensity is not high: 2025 PP&E capex was about $331 million, roughly 3.7% of revenue; under another IR basic-financials framing, capital spending sits in the low-to-mid single-digit percentage of revenue. For an industrial-technology platform, this is a solid but not "astonishingly light" cash-flow model.

If the stock market were closed for five years, would I be willing to hold this business? As a business, yes; as a stock bought at the current price, I would be more restrained. This is the most central distinction in this report. Business understandability score: 4.5/5.

Industry and Competitive Landscape

Industry Stage, Demand Stability, and Disruptability

Water-related infrastructure is not a "fast-exploding new industry"; it is more like an industry with long-term growth but a mild cadence, a public-investment character, and an overlay of upgrade cycles. Demand comes from renewing aging pipe networks, controlling leakage, upgrading wastewater treatment, improving industrial water efficiency, reuse, and upgrading monitoring and compliance. In its 2025 Infrastructure Report Card, the American Society of Civil Engineers graded drinking-water infrastructure C-, wastewater systems D+, and stormwater systems D; the EPA's Seventh Drinking Water Infrastructure Needs Survey estimates that U.S. drinking-water systems will need $625 billion of investment over 20 years. In other words, this industry is not "fashionable" but "heavily in arrears and forced to spend."

The upside of this kind of demand is that it is stable; the downside is that it is budget-driven, project-driven, and policy-driven, so the short-term recognition cadence is affected by fiscal conditions, interest rates, local budgets, project approvals, construction windows, and foreign exchange. In Q1 2026 Xylem's total revenue grew 2.7% year over year, but organic revenue was not broadly strong; in the 10-Q management explicitly noted that U.S. Water Solutions and Services capital-project revenue declined and that low starting backlog in Western Europe affected execution across multiple segments. This further shows that underlying industry demand is steady, but the quarterly cadence still fluctuates.

Technology-disruption risk is relatively manageable. Core physical steps such as pumping, filtration, metering, and treatment will not be "suddenly eliminated," but value capture will migrate from equipment alone toward "testing, software, cloud monitoring, data analytics, and outsourced services." Whoever can turn an installed base of hardware into long-term data and service revenue will deepen their moat more easily. Xylem is heading in this direction, but is still some distance from a state of "extremely deep software-based moat."

Main Competitors and Industry Position

Among public comparables, no single company overlaps completely with Xylem. Pentair is more of a water-systems solutions and partly consumer/commercial water platform; Watts Water is stronger in building water supply and drainage, fluid control, and brand channels, and reported a company ROIC of 20.5% in 2025; Badger Meter is a purer, more excellent niche leader in smart metering and water-utility digitalization, with no borrowings in 2025 and net cash of about $226 million, making its operating quality very solid. Xylem's edge is not at any single point but in platform breadth: it simultaneously covers transport, treatment, metering, monitoring, and services.

From a capital-markets comparison, at the current price Xylem's market cap of about $26.79 billion is larger than Pentair's roughly $11.86 billion, Watts' roughly $10.55 billion, and Badger Meter's roughly $3.69 billion, making it one of the largest water-technology platforms in this comparison group.

The industry's profit pool is not entirely concentrated in a single player. In certain niches, such as smart water meters and water-utility SaaS, Badger's profit quality is higher; in building water supply and drainage and valve control, Watts' capital returns are more impressive; on platform breadth and public/industrial project coverage, Xylem is more comprehensive. My judgment is that Xylem is not an "excellent company in a bad industry" but a "good company in a good industry," yet it is neither the cheapest nor the one with the most beautiful capital returns. Industry attractiveness score: 4.0/5.

Moat and Management

Moat Analysis

My overall judgment on Xylem's moat is: it exists, but it is not the "insurmountable" type; it is more of a composite moat built from installed base, customer stickiness, engineering experience, service networks, and digital capability. Its direction is broadly stable to slightly widening, especially if the share of smart metering, analytics, and service revenue keeps rising, in which case the moat will be stronger than in the pure-equipment era.

In an inflationary environment, Xylem has some pricing power. In the Q1 2026 10-Q, the company repeatedly noted that price realization hedged part of the cost and demand volatility; and in 2025 peers such as Pentair, Watts, and Badger also broadly showed margin improvement from price and efficiency, indicating this is not an industry entirely without pricing power.

Can it stay profitable in an economic downturn? The historical evidence leans positive. In 2020 Xylem still maintained positive operating profit and strong operating cash flow in a countercyclical environment; but this is not the ultra-defensive earnings stream of a utility, and project and budget disturbances still bring stage-by-stage volatility. Conclusion: it can hold up, but it is not fully immune. Moat strength score: 3.5/5.

Is Management Trustworthy and Capital Allocation Rational

On governance and incentive design, Xylem's framework is broadly acceptable. The 2026 proxy statement shows the company requires the CEO to hold shares worth 6x annual salary, and all directors and executives have met or are on track to meet the holding guidelines within a reasonable period; in 2025, about 89% and 73% of the direct compensation of the CEO and other NEOs, respectively, was performance-oriented; long-term incentives are centered on relative TSR and EPS. In 2025 shareholder Say-on-Pay support for the compensation plan was about 87%. All of this indicates a governance structure that is mainstream and long-term-oriented, rather than one that feeds the market on short-term EPS alone.

But if the bar is raised to "Buffett-style, most-demanding capital allocation," I would hold back slightly, for three reasons. First, management ownership is meaningful but not founder-level. As of March 6, 2026, CEO Matthew Pine held about 299,154 shares, and all current directors and executives together held about 786,605 shares, still less than 1% of the company's share base. In other words, there is alignment of interest, but not the kind where "management is in the same boat as you, betting most of their net worth alongside."

Second, the buyback timing does not fully satisfy me. In February 2026 the company newly authorized a $1.5 billion buyback with no expiration; by the end of Q1 2026 the company had cumulatively repurchased 4.8 million shares for $595 million. A rough calculation puts the average buyback cost at about $124/share, while the current price is about $110.1/share. At the least, this shows the latest large buyback round did not clearly occur in a significantly undervalued zone; it looks more like "buying back when there is spare capacity" than "striking hard at an obvious discount."

Third, acquisitions have created scale and capability, but have also pushed the balance sheet toward a "high goodwill / high intangibles" structure. At the end of 2022 Xylem's goodwill was $2.719 billion, rising to $7.587 billion at the end of 2023 and further to $8.332 billion at the end of 2025; over the same period net income and cash flow rose significantly, but capital returns did not rise in step to a best-in-class level. This means Evoqua is an acquisition that is possibly correct, but still needs time to prove whether it was "worth the price."

On balance, I believe management is overall acceptable on honesty and execution, and broadly rational on capital allocation, but not yet a top-tier capital allocator. Management and capital-allocation score: 3.5/5.

Financial Quality and Owner Earnings

Financial Quality Check

First the most important overall conclusion. From 2016 to 2025, Xylem's revenue grew from $3.771 billion to $9.035 billion, a ten-year compound growth rate of about 10%; but this includes the step-change jump after the 2023 Evoqua acquisition, so revenue grew faster if you look at 2021 to 2025, yet "organic, internally generated" growth should not be overstated. Operating profit rose from $406 million in 2016 to $1.192 billion in 2025, with a 2025 operating margin of about 13.2%; in the 2020 headwind year the company was still profitable with positive cash flow, showing that financial quality is not fragile.

2025 was a year of decent quality: revenue $9.035 billion, net income $957 million, operating cash flow about $1.24 billion, company-disclosed free cash flow about $910 million, dividend per share $1.60, year-end cash $1.479 billion, total debt $2.067 billion, and total shareholders' equity $11.480 billion. This shows Xylem is not the kind of company where "accounting profit looks good but cash flow is poor."

That said, three points on the financials must be seen. First, working capital consumes cash. In 2025 the combined changes in accounts receivable, accrued items, and other working capital placed a clear drag on operating cash flow; the IR cash-flow statement shows that in 2025 the impact of working-capital changes on cash was about -$334 million. This is not a red flag, but it shows this is not a "completely working-capital-free" asset-light model.

Second, the share count has not clearly shrunk. In 2021 common shares outstanding were about 180.4 million, and in 2025 about 243.6 million; although the company again repurchased a large number of shares in Q1 2026, over a longer horizon the equity dilution from the Evoqua acquisition was enormous, and historical buybacks have not produced a result of "long-term share-count compression."

Third, the quality of book net assets is mediocre. At the end of 2025 the company had goodwill of $8.332 billion and net intangibles of $2.272 billion, together $10.604 billion, almost equal to total shareholders' equity of $11.480 billion. This does not mean the company is poor; it means it is definitely not a book-asset-type bargain; your safety comes from future cash flows, not liquidation value.

To keep the framing clear, the table below uses public data from the company's IR basic-financials page and SEC disclosures; the FCF figures are approximations, estimated as "operating cash flow minus PP&E capex," used to observe the trend, not as the company's sole official non-GAAP measure.

A few key judgments. Profit is largely real cash profit. In 2025 net income was $957 million against company-disclosed free cash flow of $910 million, a modest gap; Q1 2026 operating cash flow of $108 million and free cash flow of $18 million mainly reflect seasonal working capital and buybacks, a short-term result rather than an earnings collapse.

Growth does not require very heavy capital investment. In 2025 the company's revenue of $9.035 billion corresponds to net PP&E of $1.668 billion and capex of about $331 million; this shows it is more of a "technology + equipment + service platform" than a business that must keep piling on massive heavy assets to sustain growth.

Are there signs of financial fraud, aggressive accounting, or profit manipulation? I see no obvious red flags, but I keep normal skepticism. The 2025 10-K shows the company passed its 404(b) internal-control audit and disclosed no triggering events for an executive-clawback analysis due to restatement; at the same time, goodwill and intangibles are a large share, so the biggest accounting risk is not routine fraud but that if future integration falls short, goodwill impairment would erode book earnings and market confidence.

Owner Earnings Analysis

Using the "Buffett-style Owner Earnings" approach, I would start from 2025 net income of $957 million. Among the non-cash charges to add back, the most certain are depreciation of $267 million and intangible amortization of $308 million; the company's IR cash-flow page also shows other non-cash items of about $84 million in 2025. Just these items push accounting profit up toward operating cash-generating capability.

There are two things that genuinely need to be deducted. One is maintenance capex. The company does not separately disclose maintenance capex, so this is an assumption, not a fact. To be conservative, I do not take the optimistic "deduct maintenance capex only" approach, but instead use nearly all PP&E capex to estimate it; the capex corresponding to the company's disclosed 2025 free cash flow was about $331 million, which is more conservative than deducting "only part of depreciation."

The other is working-capital consumption. In 2025 the IR cash-flow page shows working-capital changes dragged cash flow by about $334 million; but working capital fluctuates, and doing a DCF entirely on a single year's extreme value tends to understate normal years. So the more reasonable approach, when estimating true distributable cash, is to look at both the single-year fact and the normalized average.

On this basis I offer a relatively conservative Owner Earnings range: Conservative value: about $950 million. This approximates "2025 net income + depreciation and amortization + other non-cash items - all PP&E capex - 2025 working-capital consumption." Normalized value: about $1.05 billion to $1.10 billion. This is the result after treating the working-capital drag using the average of recent years. This means that at the current market cap of about $26.79 billion, Xylem trades at roughly 26x to 29x Owner Earnings. For a very poor business, this price is obviously too expensive; for a good business, it can only be called "understandable," not "a bargain in temperament."

Valuation and Margin of Safety

Intrinsic Value Estimation

I will give the conclusion first, then the method. My conclusion is: at the current price of $110.1, the stock falls in the zone that "an optimistic value can explain, while neither the conservative nor the neutral value supports an obvious margin of safety." This means you are not picking up a cigar butt; you are buying a good company at a relatively high price.

Owner Earnings Discounted Cash Flow

The three scenarios below are all modeled from an equity-cash-flow perspective, starting from the conservative or normalized Owner Earnings given above; the discount rate is based on the U.S. 10-year Treasury yield of about 4.50% as of May 26, 2026, plus a reasonable equity risk premium, so I use discount rates of 10%, 9%, and 8% respectively. The growth rate and terminal growth rate here are both assumptions, not facts. The U.S. 10-year Treasury currently yields about 4.50%.

The reading of this result is very important. At the current price of $110.1, Xylem is priced by the market closer to between neutral and optimistic, not the conservative scenario. If you are a balanced, slightly conservative long-term investor, these odds are usually not comfortable enough.

Relative Valuation

A cross-sectional comparison of "what the market pays today," using the most representative public comparables, is more intuitive. Here I prioritize the current market price alongside the cash flow, debt, equity, and capital-return data in company announcements; some peers lack a fully consistent official EV/EBITDA basis, so there are a few "not confirmed" entries in the table. This is not laziness but a way to avoid forcing inconsistent bases into precise numbers.

This table sends a very clear signal: Xylem's valuation is not low, but its capital returns are not as beautiful as Watts' or Badger's. It is not the most expensive water stock, but it is definitely not the cheapest; if you are willing to pay a premium for "platform breadth + service capability + utility exposure," that is understandable, but this is not a visible discount trade.

Asset or Liquidation Value

This method is unfriendly to Xylem, but precisely for that reason it is important. At the end of 2025 total shareholders' equity was about $11.480 billion, of which goodwill was $8.332 billion and net intangibles $2.272 billion. In other words, goodwill and intangibles together are about $10.604 billion, nearly eating up all of equity, leaving very limited tangible net assets. The company's IR ratio page shows an FY price-to-book of about 2.26x, while price-to-tangible-book is about 28.85x, essentially a reminder that this stock's investment logic must be built on future cash flows, not an asset-liquidation safety cushion.

Based on the three methods, I give the following ranges: Conservative intrinsic value range: $55-70. Fair intrinsic value range: $80-100. Optimistic intrinsic value range: $120-145. Against the current price of $110.1, I would rather define it as: slightly above neutral value, below the most optimistic value, with no obvious margin of safety.

The operational price ranges I give are: Ideal buy price range: $70-85. Acceptable holding price range: $85-105. Clearly overvalued price range: above $125. This is not a forecast of short-term moves but a "layering of odds" combining discounted cash flow, relative valuation, and asset quality.

Margin-of-Safety Assessment

Is the current price cheap enough? I think it is not. Cheapness cannot be judged by P/E alone; but when a company trades at about 27x TTM P/E and about 29x conventionally defined P/FCF while its ROE is about 9% and estimated ROIC about 8%, I find it hard to say it already offers a sufficient margin of safety to a "balanced, slightly conservative" ten-year holder.

What is the most fragile assumption in the valuation? The most fragile is not "will revenue disappear," but three things holding true at once: organic growth staying at mid-to-high single digits, acquisition integration continuing to lift margins, and the market being willing to grant it a long-term valuation premium above ordinary industrial stocks. If any one of these falls short, returns will be clearly discounted.

If growth comes in below expectations, is there still a reasonable return? If over the next 10 years Owner Earnings grow only about 4% while the exit multiple compresses to around 20x, then buying at the current $110 would likely deliver only low-to-mid single-digit long-term annualized returns, and even adding dividends the result would be "acceptable but not sexy." For an investment that bears single-company risk, this compensation is not thick enough.

If margins fall, does the investment still hold? At the business level it most likely still holds, because demand for water infrastructure will not disappear; but at the stock-return level not necessarily. Xylem is not a cheap stock now, and it has requirements of margins and execution quality. This is exactly the most common trap of "good company but bad price."

My clear judgment is: The margin of safety is not sufficient. Worth tracking, but more worth waiting for.

Risks, Counterarguments, and Comparisons

Key Risks and the Strongest Counterargument

The most important long-term risk is not price volatility but permanent loss of capital. For Xylem, the paths that lead to permanent loss are mainly the following.

Competitive risk. If higher-value links such as smart metering, leakage detection, and data platforms are taken by Badger, Watts, Veralto, or other digital players, while Xylem is still treated by the market mainly as a somewhat-better equipment maker, then its valuation premium will decline ahead of its fundamentals.

Acquisition and goodwill risk. Evoqua significantly strengthened Xylem's scale and capability, but also piled up goodwill and intangibles. If integration synergies, cross-selling, service stickiness, or margin improvement fall short, the most direct negative consequence is a mediocre ROIC while the market no longer grants a high valuation. A worse case is impairment pressure.

Overvaluation risk. This is the risk I worry about most right now. The current price looks more like "paying for high quality" than "buying a bargain amid pessimism." Once growth and margins are merely normally excellent rather than persistently above expectations, multiple compression alone is enough to swallow a large part of long-term returns.

Working-capital and project-cadence risk. The company's business includes project revenue, international operations, and budget-related orders, causing clear stage-by-stage working-capital tie-up. In 2025 working-capital changes dragged cash flow by about $334 million; in Q1 2026 free cash flow was only $18 million, showing that single-quarter cash flow can be greatly disturbed by projects and working capital.

Buyback and capital-allocation risk. The average cost of the company's large Q1 2026 buyback was roughly around $124, clearly above the current price of about $110. If it keeps buying back heavily in an overvalued zone in the future without a corresponding rise in per-share intrinsic value, that would dilute the capital-allocation score.

The strongest counterargument can be summed up in one sentence: "Xylem is a decent business, but the capital market already knows it is decent; if you buy now, what you are most likely to earn is the normal return from the company continuing to execute well, rather than the excess return from an undervaluation being corrected."

Which facts, if they appear, should make me admit I was wrong? If over the next two to three years Xylem proves it can systematically lift ROIC above low double digits on top of high goodwill, while services/software/monitoring significantly raise the share of recurring revenue and it maintains strong FCF without increasing leverage, then my "somewhat conservative valuation judgment" today may prove overly cautious. Conversely, if organic growth slows to long-term low single digits, margin improvement stalls, and ROIC lingers around 8% for a long time while the valuation stays high, then I would more clearly consider this a "good company but bad price" stock.

What is the biggest permanent-capital-loss scenario? It is not the business suddenly collapsing, but that you buy at a high valuation and then experience "growth returning to ordinary, valuation returning to ordinary, and acquisition synergies also only reaching ordinary." In this scenario the business still lives well, but shareholders' ten-year returns may be merely mediocre, or even significantly lag the index. For a value investor, this is likewise a form of capital loss.

Comparison with Other Opportunities

Compared with its closest peers, Xylem's advantage is a broader platform and more complete coverage of public and industrial water systems; its disadvantage is that the current valuation is not clearly cheaper than peers with better returns. Pentair currently trades at about 17.8x P/E and about 15.9x P/FCF, yet estimated ROIC is around 14%; Watts reported a company ROIC of 20.5% in 2025, but the market therefore grants it a high valuation too. Xylem sits in the middle: neither the cheapest nor the most profitable.

Compared with a broad index, I do not think the current odds are "clearly better than the index." The index's advantages are diversification, automatic elimination of failures, and high fault tolerance; Xylem's advantage is that you can make a clear bet on the long-term water-infrastructure logic. But for now Xylem does not offer the kind of obvious discount that would compensate for single-company risk, so I would rather view it as a high-quality industrial stock "worth tracking long term on a watch list" than a high-priority new position that must beat the index right now.

Compared with the risk-free rate, the situation is not especially favorable for buying immediately either. The U.S. 10-year Treasury was about 4.50% on May 26, 2026. If my judgment of Xylem's conservative-scenario total return is only low-to-mid single digits to mid single digits, then its extra compensation over the risk-free rate is not thick; only under the neutral and optimistic scenarios does it show a reasonable equity risk compensation.

If I could hold only 5 assets, is it qualified to enter the portfolio now? At the current price, my answer leans toward "not yet qualified"; if it returns to a more reasonable price range, it would be qualified for the candidate list.

Investment Checklist and Final Conclusion

Investment Checklist

Final Investment Conclusion

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Xylem is a high-quality water-technology business worth studying long term and possibly holding long term, but buying at the current price of about $110 offers no obvious margin of safety.

【Core Bull Case】

• Demand for water infrastructure, testing, treatment, and reuse is stable over the long term, and the U.S. water-infrastructure investment gap remains large.

• Xylem is not a single-equipment maker but an "equipment + data + service + emergency/outsourcing" platform, with strong business diversity and shock resistance.

• In 2025 the company's revenue, profit, and cash flow all reached highs, and Q1 2026 revenue and orders still grew.

• The balance sheet is solid, with year-end 2025 cash of $1.479 billion and total debt of $2.067 billion, and net debt is not high.

• The dividend record is stable, with dividend per share rising from $0.62 to $1.60 over 2016-2025.

【Core Bear Case】

• The current valuation is expensive for an industrial platform whose ROIC is still relatively ordinary, and lacks an obvious margin of safety.

• Goodwill and intangibles are an extremely high share of equity, and book assets provide little liquidation protection.

• The share count expanded significantly after the acquisition, and historical buybacks have not clearly compressed the total share count.

• The average price of the large Q1 2026 buyback was roughly above the current price, and the capital-allocation timing is not pretty.

• Working capital fluctuates a lot, and cash flow is not linear in the short term.

【Key Assumptions】

• Xylem can still maintain mid-single-digit-plus organic growth over the next decade, or improve revenue quality through services/software.

• Evoqua integration will keep improving margins and customer stickiness, rather than just bringing scale.

• The company can convert high-goodwill assets into real cash returns, rather than long-term mediocre ROIC.

• Large buybacks and future capital allocation will exercise more price discipline.

【Fair Buy Price】 The more comfortable buy range I give is $70-85; if you are willing to accept "neutral-to-optimistic" assumptions, you can treat $85-95 as a barely acceptable range, but it is no longer a "cheap buy." The basis is the conservative odds judgment reached after Owner Earnings discounting, the neutral intrinsic-value range, and peer comparison.

【Target Holding Period】 10 years or more. This stock's logic is not in trading but in whether water-infrastructure upgrades, digital penetration, and the deepening of the service business keep being delivered.

【Expected Annualized Return】 This is a model projection, not a promise.

• Conservative scenario: 3%-5%. Assumes Owner Earnings grow 4% a year and the exit valuation reverts to a more ordinary level.

• Neutral scenario: 7%-9%. Assumes Owner Earnings grow 6% a year and the valuation stays in the mid-to-high-quality industrial-stock range.

• Optimistic scenario: 11%-13%. Assumes Owner Earnings grow 8% a year, the share of services/digital rises, and the valuation keeps a premium.

【Maximum Loss Risk】 If growth slows, margin improvement stalls, and the valuation falls back from the current high to a more ordinary industrial-stock range over the next two to three years, a stage-by-stage drawdown of 30%-45% is not hard to imagine; if this is compounded by acquisition synergies falling short and a decline in market risk appetite, the drop could be deeper in extreme cases. The true long-term risk is not corporate bankruptcy but that you buy a good business at a high price and end up with only a very ordinary return.

【Tracking Metrics】 Going forward I will focus on the following metrics:

• Organic revenue growth.

• Orders and the orders/revenue ratio.

• Adjusted EBITDA margin.

• Free cash flow and FCF conversion rate.

• Working-capital tie-up, especially receivables and project-execution cadence.

• The growth quality of Measurement and Control Solutions and Water Solutions and Services.

• Whether post-acquisition ROIC keeps improving.

• Changes in share count and average buyback price.

• Net debt / EBITDA.

• Whether goodwill and intangibles show impairment pressure.

【Signals That Trigger Reassessment】 When the following occur, I will require redoing the investment work from scratch:

• Organic growth clearly below industry demand for several consecutive quarters.

• Order growth stalling or even turning negative while margins also fail to improve.

• FCF persistently and significantly below net income.

• Another large, high-premium acquisition that raises leverage.

• "Higher-quality revenue" from smart metering / analytics / services failing to keep rising.

• Goodwill impairment, or capital returns lingering at high single digits for a long time.

• Continued large buybacks at a high stock price while per-share intrinsic value does not grow in step.

【Final Recommendation】 The calm conclusion: put Xylem on a high-priority watch list, not the immediate heavy-buy list. It is a business I am willing to study long term and to own at a better price; but for "10-year-plus, balanced-and-slightly-conservative" capital, what matters more today is not proving how good it is, but acknowledging that the current price does not give you a thick-enough safety cushion. What is truly worth doing is not chasing a good story, but patiently waiting for better entry odds.

Open Questions and Data Limitations

This report still has several points that need continued updating. First, the company does not publicly and separately disclose a consistent "recurring-revenue share" or "maintenance capex," so the maintenance capex in Owner Earnings is a prudent assumption rather than an explicit company fact. Second, in the peer comparison, some EV/EBITDA and P/B metrics were not force-filled because the official bases are not fully consistent. Third, the true long-term ROIC improvement after Evoqua integration still needs another one to two full fiscal years of observation.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.